CA2376065A1 - Cristallisation et determination de structure du facteur p d'elongation du staphylococcus aureus - Google Patents

Cristallisation et determination de structure du facteur p d'elongation du staphylococcus aureus Download PDF

Info

Publication number
CA2376065A1
CA2376065A1 CA002376065A CA2376065A CA2376065A1 CA 2376065 A1 CA2376065 A1 CA 2376065A1 CA 002376065 A CA002376065 A CA 002376065A CA 2376065 A CA2376065 A CA 2376065A CA 2376065 A1 CA2376065 A1 CA 2376065A1
Authority
CA
Canada
Prior art keywords
aureus
molecule
molecular complex
binding surface
structure coordinates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376065A
Other languages
English (en)
Inventor
Timothy E. Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376065A1 publication Critical patent/CA2376065A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne le facteur P d'élongation du Staphylococcus aureus S. aureusEE-P qui a été cristallisé, et la structure cristalline à rayons X en trois dimensions a été ramenée à une résolution de 1.9 .ANG.. La structure à rayons X sert à réduire la structure d'autres molécules ou complexes moléculaires, et à concevoir des inhibiteurs de S. aureusEF-P.
CA002376065A 1999-08-06 2000-08-04 Cristallisation et determination de structure du facteur p d'elongation du staphylococcus aureus Abandoned CA2376065A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14785199P 1999-08-06 1999-08-06
US60/147,851 1999-08-06
PCT/US2000/021528 WO2001010906A1 (fr) 1999-08-06 2000-08-04 Cristallisation et determination de structure du facteur p d'elongation du staphylococcus aureus

Publications (1)

Publication Number Publication Date
CA2376065A1 true CA2376065A1 (fr) 2001-02-15

Family

ID=22523167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376065A Abandoned CA2376065A1 (fr) 1999-08-06 2000-08-04 Cristallisation et determination de structure du facteur p d'elongation du staphylococcus aureus

Country Status (5)

Country Link
EP (1) EP1200468A1 (fr)
JP (1) JP2003510250A (fr)
AU (1) AU6401200A (fr)
CA (1) CA2376065A1 (fr)
WO (1) WO2001010906A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217517B2 (en) 2001-07-23 2007-05-15 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
US7968523B2 (en) 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
CN100558410C (zh) * 2002-05-07 2009-11-11 森尼斯科技术公司 调节凋亡的核酸,多肽,以及方法
WO2004078940A2 (fr) 2003-03-05 2004-09-16 Senesco Technologies, Inc. Utilisation d'oligonucleotides antisens de siarn pour supprimer l'expression de eif-5a1
CA2717637A1 (fr) 2008-03-07 2009-09-17 Senesco Technologies, Inc. Utilisation d'arnsi pour obtenir la regulation negative d'un gene endogene en combinaison avec l'utilisation d'un produit de construction sens pour obtenir l'expression d'un polynucleotide desire
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells
US10077180B2 (en) 2016-06-02 2018-09-18 Cornelius, Inc. Beverage dispensing heads with lighting modules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147422A1 (fr) * 1999-01-27 2001-10-24 Pharmacia & Upjohn Company Dosages de modulateurs de l'activite du facteur d'elongation p

Also Published As

Publication number Publication date
AU6401200A (en) 2001-03-05
JP2003510250A (ja) 2003-03-18
WO2001010906A9 (fr) 2002-04-11
EP1200468A1 (fr) 2002-05-02
WO2001010906A1 (fr) 2001-02-15

Similar Documents

Publication Publication Date Title
Andersen et al. High resolution crystal structure of bovine mitochondrial EF-Tu in complex with GDP
US20080215249A1 (en) Crystallization and structure determination of beta secretase and/or beta secretase-like proteins
US7829303B1 (en) Ligand screening method using a crystal of beta secretase
AU782516B2 (en) Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
US6988041B2 (en) Crystallization and structure determination of Staphylococcus aureus NAD synthetase
AU6401200A (en) Crystallization and structure determination of staphylococcus aureus elongation factor
Yasutake et al. Crystal structure of the Pyrococcus horikoshii isopropylmalate isomerase small subunit provides insight into the dual substrate specificity of the enzyme
US7217556B1 (en) Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
Lohkamp et al. Three-dimensional structure of iminodisuccinate epimerase defines the fold of the MmgE/PrpD protein family
US20030199070A1 (en) Crystallization of ribosome recycling factor (RRF) and method of developing inhibitor of RRF
US6864080B2 (en) Crystallization and structure of Staphylococcus aureus peptide deformylase
US20030165984A1 (en) Hepatitis C virus helicase crystals, crystallographic structure and methods
US20030166843A1 (en) Crystallization and structure determination of staphylococcus aureus thioredoxin reductase
AU781654B2 (en) Crystallization and structure determination of staphylococcus aureus thymidylate kinase
US20020072105A1 (en) Crystallization and structure determination of FemA and FemA-like proteins
US20070020743A1 (en) Undecaprenyl pyrophosphate synthase (upps)enzyme and methods of use
US6689595B1 (en) Crystallization and structure determination of Staphylococcus aureus thymidylate kinase
US20040191271A1 (en) Crystal structures of streptococcus undecaprenyl pyrophosphate synthase and uses thereof
US20050208639A1 (en) Crystal structure of staphylococcus undecaprenyl pyrophosphate synthase and uses thereof
US20040202644A1 (en) Crystallization and structure of Staphylococcus aureus peptide deformylase
WO2002002758A2 (fr) Cristallisation et structure de la peptide deformylase du staphylocoque dore
US20040219653A1 (en) Crystal structure of homo sapiens adipocyte lipid binbing protein and uses thereof
WO2003033531A1 (fr) Proteine de liaison s8 se liant a l'arnr, tiree de la petite sous-unite ribosomale de staphylococcus aureus
von Delft et al. Structural insights into functional

Legal Events

Date Code Title Description
FZDE Dead